Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

143.69 +0.43 (+0.30%)
Streaming Delayed Price Updated: 11:22 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zoetis

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
1 Profitable Stock for Long-Term Investors and 2 Facing Headwinds
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This... 
Via MarketMinute
Topics Economy
Healthcare Sector Shines as a Defensive Anchor Amidst Market Volatility
In a period marked by broader market retreats and economic uncertainties, the healthcare sector is emerging as a beacon of resilience, demonstrating its enduring defensive nature. As of October 9,... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
How Do Investors Really Feel About Zoetis?
 
Via Benzinga
Analyst Expectations For Zoetis's Future
 
Via Benzinga
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This... 
Via MarketMinute
2 Magnificent Dividend Stocks to Buy Now and Hold Forever
Both have increased their payouts at a terrific pace over the past decade. 
Via The Motley Fool
My 2 Favorite Stocks to Buy Right Now
These two stocks will be at the top of my shortlist of stocks to add to in October. 
Via The Motley Fool
Zoetis: A Solid Investment in the Growing Pet Medicine Market?
Could Zoetis be the next big opportunity in the pet medicine market? Tune in as our experts break down the company's strengths and weaknesses. 
Via The Motley Fool
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Tech Revolutionizes Cattle Feeding: A Sustainable Future for Livestock Markets
The global cattle feeding industry is at a critical juncture, facing mounting pressures from volatile feed costs, stringent environmental regulations, and a persistent labor crunch. In response, a wave... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Emissions
2 Oversold Stocks Primed to Rebound and 1 Facing Challenges
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling... 
Via StockStory
1 of Wall Street’s Favorite Stock on Our Watchlist and 2 Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Zoetis Inc (NYSE:ZTS) Demonstrates Strong Quality Investing Traits in Caviar Cruise Screen
Zoetis (ZTS) excels in quality investing with strong revenue growth, a high 48% ROIC, and solid cash flow. Its financial health meets strict Caviar Cruise screening standards for long-term value. 
Via Chartmill
1 S&P 500 Stock Worth Investigating and 2 Facing Headwinds
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
1 Cash-Producing Stock to Consider Right Now and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
2 Reasons to Watch ZTS and 1 to Stay Cautious
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next... 
Via StockStory
Topics Government Stocks World Trade
Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q2, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
ZTS Q2 Deep Dive: Market Questions Librela Outlook Amid Double-Digit Growth in Core Franchises
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around... 
Via StockStory
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Dip into a beaten-down market sector for deals on some proven winners. 
Via The Motley Fool
If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today
The short-term picture has been less rosy than the longer-term one. 
Via The Motley Fool
3 Large-Cap Stocks with Promising Prospects
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth... 
Via StockStory
2 Stocks to Buy With $5,000 and Hold for a Decade
These two stocks come from completely different industries, but each could boost a long-term investor's returns. 
Via The Motley Fool
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness. 
Via Benzinga
Zoetis Surges After Crushing Expectations And Raising Its Outlook
The company raised its adjusted profit guidance by 10 cents at the midpoint and hiked its sales guide by $25 million. 
Via Investor's Business Daily
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Discover the top S&P500 movers in Tuesday's pre-market session.
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
Zoetis (NYSE:ZTS) Posts Better-Than-Expected Sales In Q2, Stock Soars
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue... 
Via StockStory
1 Top Dividend Growth Stock to Buy and Hold Forever
The demand for this company's products will continue increasing. 
Via The Motley Fool
IDEXX Laboratories Soars: A New Benchmark for Animal Health Diagnostics
IDEXX Laboratories (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, has sent ripples through the financial markets with an astounding 27.5% surge in its stock price. This... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.